These exons were selected based on previous reports linking BRCA1/2 alterations with sensitivity to PARP inhibitors, as well as their relevance in CNV detection models derived from ovarian cancer cell lines, which are commonly used to study therapeutic targets and molecular mechanisms of disease progression [39,40,41,42,43]. This evidence concerns the gene BRCA1 and ovarian cancer.